ArticleCancer medicine journal2022

The Evolving Role of PD-L1 Inhibition in Non-Small Cell Lung Cancer: A Review of Durvalumab and Avelumab.

Melissa Neumann et al.PubMed ↗Full text ↗

No numbers read from the abstract.